The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

August 1, 2014 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Fellow’s Forum Case Report: Arthritis, Fever, and Weight Loss In a Teenager Suggest A Rheumatic Condition
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Rheumatology Drug Updates
Explore This Issue
August 2014
Also By This Author
  • Drug Updates

Pipeline & Drug Approvals

F8-IL10 (Dekavil) is a subcutaneously administered, once-weekly agent consisting of the antiinflammatory cytokine interleukin 10 (IL-10) fused to a vascular targeting antibody (fusion protein).1 In vivo, this agent targets arthritic sites and is, therefore, currently being studied to treat rheumatoid arthritis (RA). In a small Phase 1b study, 14 of 22 patients (64%) with active RA who had failed at least one tumor necrosis factor alpha (TNF-α) inhibitor experienced beneficial results with increasing weekly doses of the agent (doses of six, 15, 30, 60, 110 and 160 mcg/kg were used). Treatment was for eight weeks. All patients received F8-IL10 along with fixed-dose methotrexate (10–15 mg/week). Among those patients who received weekly doses of 15 mcg/kg, 30 mcg/kg or 60 mcg/kg, three had American College of Rheumatology (ACR) 70 responses after seven weeks (14%). During the same time-frame, four had ACR50 responses (18%), and seven had ACR20 responses (32%). Injection-site reactions were common, occurring in 50% of patients; otherwise, F8-IL10 was well tolerated. Fifteen patients were analyzed for autoantibodies to F8-IL10, two patients showed positivity.2 Phase I studies are ongoing and currently recruiting patients.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

NB32 (bupropion/naltrexone, Contrave), an experimental obesity drug, has had its drug application review extended by the Food and Drug Administration (FDA) for another three months (to mid-September). The FDA originally rejected the drug combination in 2011, requesting long-term cardiovascular outcomes studies in obese and overweight subjects. The manufacturer worked with the FDA to develop a study that is ongoing in 8,900 patients. This study provided interim safety and cardiovascular outcomes, which were used in the agent’s resubmission data package to the FDA. The agent is currently under review in Europe.4 Risedronate 150 mg tablets (generic Actonel) for treating postmenopausal osteoporosis were recently launched in the U.S.5

Study Updates

A seven-year, open-label, extension clinical trial, PRECiSE 3 (PEGylated antibody fragment evaluation in Crohn’s disease: safety and efficacy), is evaluating the safety of the anti-TNF-α therapy certolizumab pegol in Crohn’s disease (CD).6 Results were reported recently at the Digestive Diseases Weekly Meeting in Chicago (early May). Certolizumab pegol is also FDA approved for treating RA, psoriatic arthritis and ankylosing spondylitis. This study evaluated 595 patients who received certolizumab pegol 400 mg every four weeks for up to seven years. No new safety signals were identified. Remission in CD ranged from 68–76%. A post-hoc analysis evaluated long-term outcomes in CD, stratifying patients who had received prior anti-TNF-α therapy (n=119) or who were anti-TNF-α therapy naive (n=475). The data suggest that patients who had prior anti-TNF-α therapy, had shorter remissions and a shorter mean duration of response. It is not known whether this information can be extrapolated to other disease states; however, long-term outcomes and safety information about these complex agents are always welcome in assessing patient risk vs. benefit.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis, Safety, Spondyloarthritis Tagged With: AC&R, American College of Rheumatology, Ankylosing Spondylitis, antiinflammatory, drug, EULAR, International, Kaufman, Methotrexate, Psoriatic Arthritis, Rheumatoid arthritis, rheumatologist, rheumatology, Safety, tocilizumab, weight lossIssue: August 2014

You Might Also Like:
  • Fellow’s Forum Case Report: Arthritis, Fever, and Weight Loss In a Teenager Suggest A Rheumatic Condition
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • Rheumatology Drug Updates
  • Biosimilar Drugs for RA Studied in Multiple Trials

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.